Downregulation of Epstein-Barr virus-induced gene 3 is associated with poor prognosis of hepatocellular carcinoma after curative resection

Song,Qingjie; Chen,Xi; Hu,Weidong; Mei,Guanglin; Yang,Xiaobing; Wu,Han

doi:10.3892/ol.2018.8272

Downregulation of Epstein-Barr virus-induced gene 3 is associated with poor prognosis of hepatocellular carcinoma after curative resection

Authors:
- Qingjie Song
- Xi Chen
- Weidong Hu
- Guanglin Mei
- Xiaobing Yang
- Han Wu
View Affiliations

Affiliations: Department of General Surgery, The Qidong People's Hospital and Qidong Liver Cancer Institute, Nantong, Jiangsu 226200, P.R. China, Department of General Surgery, The Affiliated Hospital of Nantong University, Nantong, Jiangsu 226001, P.R. China
Published online on: March 15, 2018 https://doi.org/10.3892/ol.2018.8272
Pages: 7751-7759
Copyright: © Song et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Epstein-Barr virus-induced gene 3 (EBI3) encodes a secretory glycoprotein, and has previously been identified as upregulated in various types of tumors. The presnet study examined the clinical significance of EBI3 expression for predicting tumor recurrence and survival after resection in hepatocellular carcinoma (HCC). EBI3 expression in various HCC cell lines and in 20 pairs of tumor and peritumor tissue samples were detected using western blot analysis. Immunohistochemical staining using tissue microarray with 312 samples from randomly selected patients with HCC who underwent surgery. Survival analysis was performed using univariate and multivariate analyses. EBI3 protein level was higher in L‑02 cells and in peri‑tumor tissues compared with tumor tissues. Immunohistochemical staining of EBI3 was reduced in HCC tissues in comparison with adjacent normal tissues and significantly associated with tumor invasive characteristics, including tumor thrombus, poor differentiation and large size. Notably, the results suggested that EBI3 was a predictor for tumor recurrence and patient survival, and multivariate analysis indicated EBI3 to be an independent prognostic factor. Even in early‑stage disease, low EBI3 expression was also independently associated with increased tumor recurrence and shortened survival. Downregulation of EBI3 in HCC indicated aggressive tumor behaviors and predicted a more severe clinical outcome, which suggests that EBI2 may be a useful biomarker to identify patients at high risk of post-operative recurrence.

View Figures

View References

1	Sun YF, Xu Y, Yang XR, Guo W, Zhang X, Qiu SJ, Shi RY, Hu B, Zhou J and Fan J: Circulating stem cell-like epithelial cell adhesion molecule-positive tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resection. Hepatology. 57:1458–1468. 2013. View Article : Google Scholar : PubMed/NCBI
2	Chen R, Cui J, Xu C, Xue T, Guo K, Gao D, Liu Y, Ye S and Ren Z: The significance of MMP-9 over MMP-2 in HCC invasiveness and recurrence of hepatocellular carcinoma after curative resection. Ann Surg Oncol. 19 Suppl 3:S375–S384. 2012. View Article : Google Scholar : PubMed/NCBI
3	Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
4	Horlad H, Ma C, Yano H, Pan C, Ohnishi K, Fujiwara Y, Endo S, Kikukawa Y, Okuno Y, Matsuoka M, et al: An IL-27/Stat3 axis induces expression of programmed cell death 1 ligands (PD-L1/2) on infiltrating macrophages in lymphoma. Cancer Sci. 107:1696–1704. 2016. View Article : Google Scholar : PubMed/NCBI
5	Collison LW, Delgoffe GM, Guy CS, Vignali KM, Chaturvedi V, Fairweather D, Satoskar AR, Garcia KC, Hunter CA, Drake CG, et al: The composition and signaling of the IL-35 receptor are unconventional. Nat Immunol. 13:290–299. 2012. View Article : Google Scholar : PubMed/NCBI
6	Vignali DA and Kuchroo VK: IL-12 family cytokines: Immunological playmakers. Nat Immunol. 13:722–728. 2012. View Article : Google Scholar : PubMed/NCBI
7	Ma Y, Chen L, Xie G, Zhou Y, Yue C, Yuan X, Zheng Y, Wang W, Deng L and Shen L: Elevated level of interleukin-35 in colorectal cancer induces conversion of T cells into iTr35 by activating STAT1/STAT3. Oncotarget. 7:73003–73015. 2016. View Article : Google Scholar : PubMed/NCBI
8	Olson BM, Jankowska-Gan E, Becker JT, Vignali DA, Burlingham WJ and McNeel DG: Human prostate tumor antigen-specific CD8+ regulatory T cells are inhibited by CTLA-4 or IL-35 blockade. J Immunol. 189:5590–5601. 2012. View Article : Google Scholar : PubMed/NCBI
9	Liang Y, Chen Q, Du W, Chen C, Li F, Yang J, Peng J, Kang D, Lin B, Chai X, et al: Epstein-Barr virus-induced gene 3 (EBI3) blocking leads to induce antitumor cytotoxic T lymphocyte response and suppress tumor growth in colorectal cancer by bidirectional reciprocal-regulation STAT3 signaling pathway. Mediators Inflamm. 2016:32141052016. View Article : Google Scholar : PubMed/NCBI
10	Nishino R, Takano A, Oshita H, Ishikawa N, Akiyama H, Ito H, Nakayama H, Miyagi Y, Tsuchiya E, Kohno N, et al: Identification of Epstein-Barr virus-induced gene 3 as a novel serum and tissue biomarker and a therapeutic target for lung cancer. Clin Cancer Res. 17:6272–6286. 2011. View Article : Google Scholar : PubMed/NCBI
11	Fan YG, Zhai JM, Wang W, Feng B, Yao GL, An YH and Zeng C: IL-35 over-expression is associated with genesis of gastric cancer. Asian Pac J Cancer Prev. 16:2845–2849. 2015. View Article : Google Scholar : PubMed/NCBI
12	Hou YM, Dong J, Liu MY and Yu S: Expression of Epstein-Barr virus-induced gene 3 in cervical cancer: Association with clinicopathological parameters and prognosis. Oncol Lett. 11:330–334. 2016. View Article : Google Scholar : PubMed/NCBI
13	Zhang Y, Sun H, Wu H, Tan Q and Xiang K: Interleukin 35 is an independent prognostic factor and a therapeutic target for nasopharyngeal carcinoma. Contemp Oncol (Pozn). 19:120–124. 2015.PubMed/NCBI
14	Jin P, Ren H, Sun W, Xin W, Zhang H and Hao J: Circulating IL-35 in pancreatic ductal adenocarcinoma patients. Hum Immunol. 75:29–33. 2014. View Article : Google Scholar : PubMed/NCBI
15	Wang Z, Liu JQ, Liu Z, Shen R, Zhang G, Xu J, Basu S, Feng Y and Bai XF: Tumor-derived IL-35 promotes tumor growth by enhancing myeloid cell accumulation and angiogenesis. J Immunol. 190:2415–2423. 2013. View Article : Google Scholar : PubMed/NCBI
16	Zeng JC, Zhang Z, Li TY, Liang YF, Wang HM, Bao JJ, Zhang JA, Wang WD, Xiang WY, Kong B, et al: Assessing the role of IL-35 in colorectal cancer progression and prognosis. Int J Clin Exp Pathol. 6:1806–1816. 2013.PubMed/NCBI
17	Fu YP, Yi Y, Cai XY, Sun J, Ni XC, He HW, Wang JX, Lu ZF, Huang JL, Cao Y, et al: Overexpression of interleukin-35 associates with hepatocellular carcinoma aggressiveness and recurrence after curative resection. Br J Cancer. 114:767–776. 2016. View Article : Google Scholar : PubMed/NCBI
18	Long J, Guo H, Cui S, Zhang H, Liu X, Li D, Han Z, Xi L, Kou W, Xu J, et al: IL-35 expression in hepatocellular carcinoma cells is associated with tumor progression. Oncotarget. 7:45678–45686. 2016. View Article : Google Scholar : PubMed/NCBI
19	Wu H, Shi XL, Zhang HJ, Song QJ, Yang XB, Hu WD, Mei GL, Chen X, Mao QS and Chen Z: Overexpression of ST3Gal-I promotes migration and invasion of HCCLM3 in vitro and poor prognosis in human hepatocellular carcinoma. Onco Targets Ther. 9:2227–2236. 2016. View Article : Google Scholar : PubMed/NCBI
20	Huang J, Fan X, Wang X, Lu Y, Zhu H, Wang W, Zhang S and Wang Z: High ROR2 expression in tumor cells and stroma is correlated with poor prognosis in pancreatic ductal adenocarcinoma. Sci Rep. 5:129912015. View Article : Google Scholar : PubMed/NCBI
21	Qi X, Jia J, Fan D and Han G: Brivanib for hepatocellular carcinoma trials: Selection bias from barcelona clinic liver cancer stage. J Clin Oncol. 32:9682014. View Article : Google Scholar : PubMed/NCBI
22	Lim KC, Wang VW, Siddiqui FJ, Shi L, Chan ES, Oh HC, Tan SB and Chow PK: Cost-effectiveness analysis of liver resection versus transplantation for early hepatocellular carcinoma within the Milan criteria. Hepatology. 61:227–237. 2015. View Article : Google Scholar : PubMed/NCBI
23	Chen G, Liang Y, Guan X, Chen H, Liu Q, Lin B, Chen C, Huang M, Chen J, Wu W, et al: Circulating low IL-23: IL-35 cytokine ratio promotes progression associated with poor prognosisin breast cancer. Am J Transl Res. 8:2255–2264. 2016.PubMed/NCBI